The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on the ...

Spread the loveBoston Scientific, headquartered in Marlborough, has seen its stock surge by 50%, driven by a series of ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...